16 completed, 12 withdrawn, 8 terminated, 4 unknown. 42 Phase 2, 15 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Completed 16, Withdrawn 12, Terminated 8, Unknown 4, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 15 | Withdrawn 10, Terminated 3, Completed 2 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Omacor: new trials by email Literature Review of Omacor trials Research Report on Omacor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium | Phase 2 | Terminated | University of Missouri-Columbia | 1 | 2026-03-03 | 2026-05-11 |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters - Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-07-28 | 2026-08-04 |
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Altering Lipids for Tolerance of Aromatase Inhibitor Therapy Omega-3 fatty acid supplement - Breast Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 77 | 2020-07-28 | 2026-05-06 |
| Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE) Multi-modal intervention - Gastric Cancer, Colorectal Cancer | Phase 2 | Unknown | Kil Yeon Lee | 112 | 2020-01-31 | 2021-06-01 |
| Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers Curcumin C3 complex®, Lovaza®, Placebo - Lung Diseases, Lung Cancer, Protection Against | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 19 | 2019-06-05 | 2026-02-27 |
| Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) Omega-3 fatty acid ethyl esters (2 gram) - Colorectal Cancer, Lynch Syndrome | Phase 2 | Unknown | University of Kansas Medical Center | 21 | 2019-02-06 | 2023-06-01 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC avelumab, bevacizumab, capecitabine - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-02-01 | 2025-02-21 | |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 4 | 2017-12-28 | 2024-05-22 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Melanoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy Avelumab, Bevacizumab, Capecitabine - Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Merkel Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy avelumab, bevacizumab, capecitabine - Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy ALT-803, ETBX-011, GI-4000 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 6 | 2017-11-06 | 2024-12-12 |
| Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury Omega 3 fatty acid, Safflower seed oil - TBI | Phase 2 | Withdrawn | University of Pennsylvania | 2017-01-01 | 2022-10-13 | |
| Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study Omega-3 - Epilepsy | Phase 2 | Unknown | Seoul National University Hospital | 30 | 2016-08-01 | 2018-04-20 |
Showing 20 of 42. Sign in to see all of them.
Breast Neoplasms (5) · Hypertriglyceridemia (5) · Colorectal Neoplasms (4) · Pancreatic Neoplasms (3) · Cardiovascular Diseases (2) · Depression (2) · Lung Neoplasms (2) · Myocardial Infarction (2) · Acute Coronary Syndrome (1) · Biliary Tract Neoplasms (1) · Body Weight (1) · Breast Carcinoma In Situ (1) · Cachexia (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Merkel Cell (1)
ImmunityBio, Inc. (11) · AstraZeneca (2) · Boston Children's Hospital (2) · Carol Fabian, MD (2) · Medical University of Vienna (2) · University of Rochester (2) · Babu Balagopal (1) · Columbia University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Invitrox (1) · Kil Yeon Lee (1) · National Cancer Institute (NCI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novartis Pharmaceuticals (1) · Prisma Health-Midlands (1)
United States (26) · Austria (2) · South Korea (2) · Canada (1) · Denmark (1) · Hungary (1) · Iraq (1) · Latvia (1) · Poland (1) · Russia (1) · Slovakia (1) · Sweden (1)
Carol Fabian, MD (2) · Anwaar Saeed, MD (1) · Christopher C Cheatham, Ph.D. (1) · Daniel T Johnston, MD, MPH (1) · Dawn Hershman, MD (1) · Grace McComsey, MD (1) · Gregory C Shearer, PhD (1) · Harvey J Murff, MD, MPH (1) · J. Benjamin Jackson, MD (1) · Kil Yeon Lee, M.D. (1) · Kon Chu, MD, PhD (1) · Lauren Nye (1) · Lynn Henry, MD, PhD (1) · Marlene P Freeman, M.D. (1) · Mauricio Cohen, MD (1)
PMID 17699247, PMID 21570522, PMID 21621252, PMID 21870979, PMID 23034965, PMID 23312053, PMID 23372745, PMID 25393536, PMID 29802077, PMID 34291724, PMID 35410294, PMID 38299639
2014 (1), P30CA046592 (1), R01CA160938 (1), R01DK049368 (1), UG1CA242632 (1)